CHRISTOPHER MOYER

Monitored the introduction of drug pricing legislation for its potential impact on existing and emerging cancer drug therapies and site neutrality. Monitored Medicare reimbursement developments in the agencies and Congress for alternative cancer therapies, such as CAR-T.

The President's FY 2020 Budget as it relates to site neutral payment policies and funding for the National Institutes of Health, monitored the introduction of drug pricing legislation for its potential impact on existing and emerging cancer drug therapies. Monitored Medicare reimbursement developments in the agencies and Congress for alternative cancer therapies, such as CAR-T.

The President's FY 2020 Budget as it relates to site neutral payment policies and funding for the National Institutes of Health, monitored the introduction of drug pricing legislation for its potential impact on existing and emerging cancer drug therapies

FY 2018 Continuing Resolution, budget agreement, the omnibus FY 2018 appropriations bill and the President's FY 2019 Budget as they relate to site neutrality payment policies and funding the National Institutes of Health.

FY 2018 Continuing Resolution, budget agreement, the omnibus FY 2018 appropriations bill and the President's FY 2019 Budget as they relate to site neutrality payment policies and funding the National Institutes of Health.

FY 2018 Continuing Resolution, budget agreement, the omnibus FY 2018 appropriations bill and the President's FY 2019 Budget as they relate to site neutrality payment policies and funding the National Institutes of Health.

FY 2018 Continuing Resolution, budget agreement, the omnibus FY 2018 appropriations bill and the President's FY 2019 Budget as they relate to site neutrality payment policies and funding the National Institutes of Health.

American Health Care Act, the Better Care Reconciliation Act, the Obamacare Repeal Reconciliation Act and the Tax Cuts & Jobs Act as they relate to patient access and affordability to specialized cancer treatment and the adequacy of provider networks.

American Health Care Act, the Better Care Reconciliation Act and the Obamacare Repeal Reconciliation Act as they relate to patient access and affordability to specialized cancer treatment and the adequacy of provider networks.

American Health Care Act as it relates to patient access and affordability to specialized cancer treatment and the adequacy of provider networks.

American Health Care Act as it relates to patient access and affordability to specialized cancer treatment and the adequacy of provider networks.

21st Century Cures Act to include the language of Section 202 of H.R. 5273, the Helping Hospitals Improve Patient Care Act of 2016 to exempt dedicated cancer centers from the site-neutral payment changes enacted by Section 603 of the Bipartisan Budget Act of 2015.

Section 202 of H.R. 5273, the Helping Hospitals Improve Patient Care Act of 2016 to exempt dedicated cancer centers from the site-neutral payment changes enacted by Section 603 of the Bipartisan Budget Act of 2015.

Section 202 of H.R. 5273, the Helping Hospitals Improve Patient Care Act of 2016 to exempt dedicated cancer centers from the site-neutral payment changes enacted by Section 603 of the Bipartisan Budget Act of 2015.

Section 603 of the Bipartisan Budget Act of 2015 regarding changes in payments to hospital outpatient departments

SGR Repeal & Medicare Beneficiary Access Improvement Act of 2013

HR 2869, the proposed Medicare Patient Access to Cancer Treatment Act of 2013, that would equalize Medicare reimbursements for cancer services between hospital outpatient departments and physician offices.

BUD - federal budget for NIH/NCI; HCR - cancer; INS - health insurance exchanges; MED - clinical trials; MMM - payment rates

BUD - federal budget for NIH/NCI; HCR - cancer; INS - health insurance exchanges; MED - clinical trials; MMM - payment rates

BUD - federal budget for NIH/NCI; HCR - cancer; INS - health insurance exchanges; MED - clinical trials; MMM - payment rates